scholarly article | Q13442814 |
P356 | DOI | 10.1158/1078-0432.CCR-10-0720 |
P698 | PubMed publication ID | 21325072 |
P2093 | author name string | Lan Wang | |
Jun Li | |||
Huaping Xiong | |||
Libing Song | |||
Mengfeng Li | |||
Wenting Liao | |||
Jueheng Wu | |||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lung cancer | Q47912 |
apoptotic process | Q14599311 | ||
NF-κB | Q411114 | ||
P304 | page(s) | 1839-1849 | |
P577 | publication date | 2011-02-15 | |
P1433 | published in | Clinical Cancer Research | Q332253 |
P1476 | title | Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer | |
P478 | volume | 17 |
Q41661043 | "Dicing and Splicing" Sphingosine Kinase and Relevance to Cancer. |
Q38730904 | 17β-Estradiol Inhibites Tumor Necrosis Factor-α Induced Apoptosis of Human Nucleus Pulposus Cells via the PI3K/Akt Pathway |
Q30408967 | A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis. |
Q37448046 | A novel sphingosine kinase 1 inhibitor (SKI-5C) induces cell death of Wilms' tumor cells in vitro and in vivo |
Q36216032 | ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer |
Q52663621 | ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer. |
Q36886386 | Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2. |
Q37711623 | Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer |
Q35268434 | An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma |
Q38436627 | Analysis of gene expression changes associated with human carcinoma-associated fibroblasts in non-small cell lung carcinoma |
Q35568516 | Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. |
Q59797966 | Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro |
Q34591058 | Baicalein induces apoptosis in esophageal squamous cell carcinoma cells through modulation of the PI3K/Akt pathway |
Q39381472 | Bufalin induces lung cancer cell apoptosis via the inhibition of PI3K/Akt pathway |
Q55068125 | Citrus nobiletin ameliorates experimental colitis by reducing inflammation and restoring impaired intestinal barrier function. |
Q34982814 | Comparative transcriptome profiling of an SV40-transformed human fibroblast (MRC5CVI) and its untransformed counterpart (MRC-5) in response to UVB irradiation |
Q99241043 | Discovery of Harmaline as a Potent Inhibitor of Sphingosine Kinase-1: A Chemopreventive Role in Lung Cancer |
Q40574345 | Docosahexaenoic Acid Induces Cell Death in Human Non-Small Cell Lung Cancer Cells by Repressing mTOR via AMPK Activation and PI3K/Akt Inhibition |
Q37364111 | Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. |
Q37215717 | EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma. |
Q34168267 | ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer |
Q26863646 | Evolving concepts in cancer therapy through targeting sphingolipid metabolism |
Q27009557 | Export of sphingosine-1-phosphate and cancer progression |
Q101390679 | GDC-0349 inhibits non-small cell lung cancer cell growth |
Q33275396 | High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis |
Q39126225 | Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma |
Q37046483 | Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells |
Q64973473 | Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer. |
Q34373466 | Interdiction of sphingolipid metabolism to improve standard cancer therapies |
Q37716622 | Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro |
Q33829692 | Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget |
Q39377954 | Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent. |
Q52653066 | Nimotuzumab enhances the sensitivity of non-small cell lung cancer cells to tumor necrosis factor-α by inhibiting the nuclear factor-кB signaling pathway. |
Q56387433 | Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era |
Q38092176 | Oncogenic properties of sphingosine kinases in haematological malignancies. |
Q36579625 | Phosphorylation of IκBα at serine 32 by T-lymphokine-activated killer cell-originated protein kinase is essential for chemoresistance against doxorubicin in cervical cancer cells |
Q42931095 | RNA interference-mediated knockdown of Aurora-B alters the metastatic behavior of A549 cells via modulation of the phosphoinositide 3-kinase/Akt signaling pathway |
Q33649823 | Re-configuration of sphingolipid metabolism by oncogenic transformation |
Q35817821 | Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer |
Q36729492 | SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A |
Q38925751 | SPHK1 inhibitor suppresses cell proliferation and invasion associated with the inhibition of NF-κB pathway in hepatocellular carcinoma |
Q34227524 | SPHK1 regulates proliferation and survival responses in triple-negative breast cancer |
Q39607440 | Sensitization of human colon cancer cells to sodium butyrate-induced apoptosis by modulation of sphingosine kinase 2 and protein kinase D. |
Q36356934 | Shaping the landscape: metabolic regulation of S1P gradients |
Q33827178 | Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC. |
Q27026103 | Sphingolipids in spinal cord injury |
Q35794452 | Sphingosine kinase 1 as an anticancer therapeutic target |
Q33853998 | Sphingosine kinase 1 in cancer |
Q37697046 | Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma. |
Q36772101 | Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression |
Q33636769 | Sphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer |
Q34428778 | Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation |
Q90326756 | Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma |
Q54977790 | Sphingosine kinase 1 overexpression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma. |
Q39105266 | Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells |
Q92683744 | Sphingosine kinase-1 predicts overall survival outcomes in non-small cell lung cancer patients treated with carboplatin and navelbine |
Q35661485 | Sphingosine-1-phosphate signaling and its role in disease |
Q50665340 | Sphingosine-1-phosphate/sphingosine kinase 1-dependent lymph node metastasis in esophageal squamous cell carcinoma. |
Q37905015 | Still benched on its way to the bedside: sphingosine kinase 1 as an emerging target in cancer chemotherapy |
Q49714600 | TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition |
Q35789935 | Targeting sphingosine kinase-1 to inhibit melanoma. |
Q34449722 | Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells |
Q26748848 | The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined |
Q26748927 | The emerging role of FTY720 (Fingolimod) in cancer treatment |
Q35838573 | The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses |
Q38915115 | Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism |
Q37930972 | Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer |
Q59354243 | Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice |
Q36385420 | Transient receptor potential channel 1 maintains adherens junction plasticity by suppressing sphingosine kinase 1 expression to induce endothelial hyperpermeability. |
Q55044083 | Veratric Acid Inhibits LPS-Induced IL-6 and IL-8 Production in Human Gingival Fibroblasts. |
Q34888009 | Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway |
Q91737812 | circ_0003418 Inhibits Tumorigenesis And Cisplatin Chemoresistance Through Wnt/β-Catenin Pathway In Hepatocellular Carcinoma |
Q39373595 | miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. |
Q36231932 | p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways |
Q34163536 | p53-Dependent transcriptional responses to interleukin-3 signaling |
Search more.